DGAP-News: Epigenomics AG Reports Financial Results for the First Six Months of 2022
Retrieved on:
Wednesday, August 10, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, FSE, Epigenomics AG, CEO, Center for Medicare and Medicaid Innovation, Medicare, Legislation, Board of directors, Technology, CE marking, EUR, Clinical trial, Cancer, Center, DGAP, Congress, AG, Method, ECX, Marketing, EBITDA, DNA, Company, Next Generation, CET, News, IFRS, CMS, General officer, Research, Webcast, Liver cancer, COVID-19, Goal, Section 92 of the Constitution of Australia, EDT, Colorectal cancer, 970, Administration, Food, OTCQX, Security (finance), Renewable energy, Film, Cryptocurrency, Pharmaceutical industry, Audit, Epigenomics
Berlin (Germany) and San Diego, CA (U.S.A.), August 10, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2022.
Key Points:
- Berlin (Germany) and San Diego, CA (U.S.A.), August 10, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2022.
- Epigenomics AG assumes that given the planned financial development, a cumulative loss of more than half of the nominal share capital will occur in the near future.
- The interim statement for the first six months 2022 (unaudited) can be found on Epigenomics' website at: https://www.epigenomics.com/news-investors/financial-reports/ .
- Epigenomics AG will host a conference call for analysts and investors today at 4.00 pm (CET) / 10.00 am (EDT).